Navigation Links
Mindray Announces 2008 Fourth Quarter and Full Year Results
Date:3/4/2009

ed in 2008. This guidance reflects an assumption that foreign exchange rates remain constant at RMB6.85 to the dollar and $1.28 to the euro.

The company also expects its full year 2009 non-GAAP EPS to grow 20% over its non-GAAP EPS for full year 2008.

The company expects its capital expenditure for 2009 to be in the range of $40 million to $60 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

"Despite the continued economic challenges we are all witnessing, we are confident Mindray can achieve at least 20% revenue growth in 2009, with stronger growth coming in the second half of the year," commented Mr. Li Xiting, Mindray's president and co-chief executive officer. "For 2009, we will continue to work towards a successful integration of DPM to improve our product and geographic mix and offer cross-selling and market share gain opportunities. We hope to gain market share based on the increasing attractiveness of our high performance-price products to an increasingly cost-conscious customer base. In addition, to improve our international distribution platform, we plan to expand and localize our international distribution teams at reasonable costs. Mindray is well positioned to navigate these unprecedented times and to capitalize on any opportunities that may emerge because of the diversity of our product offering across a range of price points, our ability to closely manage costs, and the strength of our balance sheet."

Conference Call Information

Mindray's management will hold an earnings conference call at 8:00 AM on March 5, 2009 U.S. Eastern Time (9:00 PM on March 5, 2009 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    Hong Kong:                +852-3002-1672
    U.S. Tol
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Mindray Medical International Announces Second Quarter 2008 Results
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. Mindray Medical International Announces First Quarter 2008 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces Third Quarter 2007 Results
6. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Martek Announces First Quarter 2009 Financial Results
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... May 25, 2011 /PRNewswire/ -- Vermillion, ... today announced that the United States Patent and Trademark Office ... entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s Disease." ... as well as combinations that include these biomarkers. ...
... 2011 VIVUS, Inc. (NASDAQ: ... 3, placebo-controlled clinical trial of the investigational drug avanafil ... following a radical prostatectomy. The study (REVIVE-RP, TA-303) met ... erectile function as measured by the Sexual Encounter Profile ...
... 24, 2011 Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – today announced ... rule 5550(a)(2), which concerns minimum bid price listing ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 2VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 4VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 5Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... wildlife while feeding a world population predicted to ... holistic approach to conservation that considers human-altered landscapes ... Wildlife and the natural habitat that supports it ... world where at least three-quarters of the land ... rest is vulnerable to human-caused impacts such as ...
(Date:4/18/2014)... Ancient DNA adds a twist to the story of how ... published April 21 in the journal Proceedings of the ... bones of chickens that lived 200-2300 years ago in Europe, ... chickens may have looked far different from the chickens we ... traits we associate with modern domestic chickens -- such as ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2
... a well known cell surface protein inhibited prostate cancer ... disease that did not respond to hormone therapy, according ... of Urology and UCLA,s Jonsson Comprehensive Cancer Center. ... up regulated or turned on in prostate cancer that ...
... PHILADELPHIA Molecular biologist Jonathan Brody, Ph.D., ... Goney, Ph.D., research assistant professor, and member of ... in the Department of Pathology, Anatomy and Cell ... University have been awarded a W.W. Smith Charitable ...
... blood "metabolomics" profile of smokers immediately after they ... in cell death, inflammation, and other forms of ... Cancer Center, part of Georgetown University Medical Center. ... the Ninth AACR Frontiers in Cancer Prevention Research ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Jefferson researchers receive W.W. Smith Charitable Trust 2Jefferson researchers receive W.W. Smith Charitable Trust 3Studying the metabolome of smokers, Lombardi researchers find early signs of damage 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and ... genomics, proteomics and drug development laboratories. ... of instrumentation to automate basic liquid ... Mini-Workstations are controlled with either Caliper's ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: